Phase II
Aptinyx therapeutic NYX-2925, intended to treat painful diabetic peripheral neuropathy failed to produce significant results. Here is why it happened.
Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.
Speakers at the 2022 Virtual Growth Conference’s session on pancreatic cancer acknowledged the exceptional challenges while extolling advances in immune-based therapies and combination approaches.
This morning, Merck hosted a cardiovascular investment event where it touted the advances it’s made in its pipeline, which includes a portfolio that has tripled in size over the past year.
Discover what’s in store for today’s presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
Imara stock plunged 40% after announcing the failure of Phase II sickle cell and beta-thalassemia trials and plans to discontinue development.
The company’s shares rose by 29.6% on NASDAQ shortly after the announcement.
Alcohol use disorder is common among the population for a very long time. Adial is planning to leverage genomics that can treat pervasive alcohol use disorder.
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
Three studies supporting Merck and Ridgeback Biotherapeutics’ Lagevrio (molnupiravir) will be presented at the ECCMID 2022 in Lisbon from April 23-26.
PRESS RELEASES